Explore strategies for controlling COPD and improving health, with a focus on management and lifestyle changes.

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...

As ICSs treat COPD exacerbations, people on ICSs could have fewer coded ... Second, an important question arising from this research is whether medication response is influenced by demographics or ...

The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

The following is a summary of “Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe ...

“We are proud to continue advancing our asthma and COPD inhaled drug program, achieving key clinical development milestones on schedule,” said Xian-Ming Zeng, Ph.D., CEO of Transpire Bio.

New drugs for COPD are currently being studied ... such as patients with sputum eosinophilia or with a high rate of exacerbations. Despite the poor advances in the pharmacologic therapy, other ...